Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 9/2019

01-09-2019 | Anaphylaxis | Commentary

Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France

Authors: Damien Botsen, Elise Lepoix, Camille Mazza, Mathilde Brasseur, Anne Grange, Florian Slimano, Olivier Bouché

Published in: Supportive Care in Cancer | Issue 9/2019

Login to get access

Abstract

This study was undertaken to assess the previously unevaluated safety and feasibility of oxaliplatin-desensitization procedure add a French ambulatory cancer unit, which is a current topic in oncology. Our findings demonstrated that oxaliplatin-desensitization was safe and feasible in our ambulatory cancer unit. In routine practice, all these procedures are done on an inpatient basis starting at least the day before. Those results could change oncological practices in France and improve patients’ quality of life and lower costs associated with inpatient administration.
Literature
1.
André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351CrossRef
2.
Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8(2):106–109CrossRefPubMed
3.
Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89(3):477–481CrossRefPubMedPubMedCentral
4.
Hong DI, Dioun AF (2014) Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract 2(1):13–19 quiz 20CrossRefPubMed
5.
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574–580CrossRefPubMed
6.
Wong JT, Ling M, Patil S, Banerji A, Long A (2014) Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2(1):40–45CrossRefPubMed
7.
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Protocol Development (2010) | CTEP
8.
Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, Gomez de Salazar E, Alvarez-Cuesta E (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68(7):853–861CrossRefPubMed
9.
Le Roy F, Rigault E, Regnault D, Hubert N, Burtin P, Hollebecque A, Malka D, Boige V, Ducreux M (2018) Oxaliplatin desensitization after hypersensitivity reaction: a single-center experience on more than 300 procedures. J Clin Oncol 36(4_suppl):610–610CrossRef
Metadata
Title
Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France
Authors
Damien Botsen
Elise Lepoix
Camille Mazza
Mathilde Brasseur
Anne Grange
Florian Slimano
Olivier Bouché
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-019-04863-5

Other articles of this Issue 9/2019

Supportive Care in Cancer 9/2019 Go to the issue

Original Article

Neuropathic symptoms, physical and emotional well-being, and quality of life at the end of life

Original Article

Patient perspectives on adapting meaning-centered psychotherapy in advanced cancer for the Chinese immigrant population

Original Article

Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma

Original Article

Fear of disease progression in adult ambulatory patients with brain cancer: prevalence and clinical correlates

Original Article

Predictors of fatigue in cancer patients: a longitudinal study

Correction

Correction to: High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits